Brokerages expect that Crispr Therapeutics AG (NASDAQ:CRSP) will report earnings of ($0.92) per share for the current quarter, according to Zacks Investment Research. Two analysts have made estimates for Crispr Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.73) and the lowest estimate coming in at ($1.01). Crispr Therapeutics posted earnings per share of ($0.82) in the same quarter last year, which suggests a negative year-over-year growth rate of 12.2%. The company is scheduled to report its next earnings results on Tuesday, August 6th.

According to Zacks, analysts expect that Crispr Therapeutics will report full year earnings of ($3.82) per share for the current year, with EPS estimates ranging from ($4.18) to ($3.17). For the next year, analysts expect that the firm will report earnings of ($4.26) per share, with EPS estimates ranging from ($5.04) to ($3.24). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that that provide coverage for Crispr Therapeutics.

Crispr Therapeutics (NASDAQ:CRSP) last announced its quarterly earnings data on Monday, April 29th. The company reported ($0.93) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.90) by ($0.03). The business had revenue of $0.30 million during the quarter, compared to analyst estimates of $1.50 million. Crispr Therapeutics had a negative return on equity of 50.90% and a negative net margin of 8,839.02%. The business’s revenue for the quarter was down 78.6% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.62) EPS.

Several equities analysts have recently issued reports on the stock. BidaskClub raised shares of Crispr Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 14th. Zacks Investment Research cut shares of Crispr Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, April 29th. William Blair assumed coverage on shares of Crispr Therapeutics in a research note on Wednesday, March 13th. They issued a “market perform” rating on the stock. BTIG Research assumed coverage on shares of Crispr Therapeutics in a report on Thursday, February 7th. They issued a “buy” rating and a $43.00 target price for the company. Finally, Evercore ISI assumed coverage on shares of Crispr Therapeutics in a report on Thursday, April 11th. They issued an “outperform” rating for the company. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and seven have given a buy rating to the stock. Crispr Therapeutics has a consensus rating of “Hold” and an average price target of $47.64.

In other Crispr Therapeutics news, President Rodger Novak sold 85,220 shares of the firm’s stock in a transaction dated Monday, March 4th. The shares were sold at an average price of $40.40, for a total value of $3,442,888.00. Following the completion of the transaction, the president now directly owns 1,024,534 shares in the company, valued at $41,391,173.60. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, CEO Samarth Kulkarni sold 20,000 shares of the firm’s stock in a transaction dated Monday, April 29th. The stock was sold at an average price of $42.03, for a total transaction of $840,600.00. Following the completion of the transaction, the chief executive officer now owns 186,542 shares of the company’s stock, valued at $7,840,360.26. The disclosure for this sale can be found here. Company insiders own 37.70% of the company’s stock.

Hedge funds have recently bought and sold shares of the stock. Versant Venture Management LLC boosted its stake in shares of Crispr Therapeutics by 17.7% in the 1st quarter. Versant Venture Management LLC now owns 4,248,888 shares of the company’s stock valued at $151,770,000 after purchasing an additional 640,014 shares in the last quarter. ARK Investment Management LLC boosted its position in Crispr Therapeutics by 52.7% during the 1st quarter. ARK Investment Management LLC now owns 2,023,017 shares of the company’s stock worth $72,262,000 after acquiring an additional 697,907 shares during the last quarter. Wellington Management Group LLP boosted its position in Crispr Therapeutics by 72.9% during the 1st quarter. Wellington Management Group LLP now owns 1,454,630 shares of the company’s stock worth $51,959,000 after acquiring an additional 613,192 shares during the last quarter. Ontario Teachers Pension Plan Board acquired a new position in Crispr Therapeutics during the 4th quarter worth approximately $16,598,000. Finally, Two Sigma Investments LP boosted its position in Crispr Therapeutics by 25.2% during the 4th quarter. Two Sigma Investments LP now owns 509,572 shares of the company’s stock worth $14,558,000 after acquiring an additional 102,478 shares during the last quarter. Institutional investors and hedge funds own 48.96% of the company’s stock.

Shares of CRSP traded down $1.02 during mid-day trading on Friday, hitting $35.57. The company’s stock had a trading volume of 306,072 shares, compared to its average volume of 378,694. The stock has a market capitalization of $1.94 billion, a P/E ratio of -10.34 and a beta of 3.11. The company has a debt-to-equity ratio of 0.08, a current ratio of 15.84 and a quick ratio of 15.84. Crispr Therapeutics has a fifty-two week low of $22.22 and a fifty-two week high of $73.88.

Crispr Therapeutics Company Profile

CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for the treatment of serious human diseases using its regularly interspaced short palindromic repeats associated protein-9 (CRISPR/Cas9) gene-editing platform in Switzerland. Its lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from dependent beta thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells.

Recommended Story: What is a put option?

Get a free copy of the Zacks research report on Crispr Therapeutics (CRSP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Crispr Therapeutics (NASDAQ:CRSP)

Receive News & Ratings for Crispr Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.